SCHEMBL1640552

SCHEMBL1640552

CC(NC(=O)c1cn(Cc2ccccc2)c(=O)cc1O)c1ccc(Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 8/20 0.50
PTGDR Q13258 6/20 0.50
MAPT P10636 1/20 0.47
USP10 Q14694 2/20 0.47
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.46
P2RX3 P56373 2/20 0.46
PDE10A Q9Y233 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
TP53 P04637 1/20 0.44
PDE2A O00408 1/20 0.44
THRB P10828 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1641854 0.93 KDM4E (0.53) PTGER4PTGDRMAPTKDM4EALDH1A1
SCHEMBL1640540 0.93 KDM4E (0.53) PTGER4PTGDRMAPTKDM4EALDH1A1
SCHEMBL1641721 0.93 KDM4E (0.53) PTGER4PTGDRMAPTKDM4EALDH1A1
SCHEMBL1641827 0.85 BRD4 (0.57) MAPTP2RX3MEN1KMT2A
SCHEMBL1640573 0.79 BRD4 (0.65) MAPTALDH1A1LMNAHPGD
SCHEMBL1640357 0.77 EGLN3 (0.66) PTGER4PTGDRUSP10MEN1KMT2A
SCHEMBL1642053 0.76 MAPT (0.59) MAPTKDM4EALDH1A1LMNAHPGD
SCHEMBL1640326 0.76 HSP90AA1 (0.58) MAPTKDM4EALDH1A1LMNAHPGD
SCHEMBL1642389 0.75 EGLN1 (0.48) ALDH1A1
SCHEMBL1640352 0.75 LMNA (0.55) MAPTKDM4EALDH1A1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 PTGER4 1880/4885PTGDR 899/4885MAPT 4716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.